You are here:
- Home
- News
-
ESME to close
The board members and volunteers of ESME would like to inform you that we will be closing ESME (the European Society for ME) before the end of 2012. ESME’s website will be accessible for approximately 1 year, but no new information will be added. The donations that were given to ESME will be given to a project to test Rituximab, as we believe this project has the potential to benefit all ME patients.
-
Persbericht: Petitie ME-patiënten: Erken ME als invaliderende biomedische ziekte
Press release by ME-DenHaag for political petition for recognizing ME, 27 jan 2012
-
Response to ‘A controversial consensus’; By the International Consensus Panel, Journal of Internal Medicine
By Dr G. Broderick, JOurnal of Internal Medicine, January 2012
-
A controversial consensus – comment on article by Broderick et al, Journal of Internal Medicine
By J. W. M. van der Meer, A. R. Lloyd, Journal of internal Medicine, January 2012
-
Flyer of the Dutch Petition for recognizing ME as a biological disease
You can print this out for your doctor, family, friends and more.
-
Dutch Politicial Petition for recognizing ME as Biomedical disease
-
All information about the breakthrough of Rutiximab as possible treatment for ME patients from the Norwegian Dr.Mella and Dr. Fluge
Norwegian and english translations of articles and video`s from TV2. With a lot of thanks to TV 2, Norway, they did a wonderful job.
-
Norwegian research breakthrough can solve CFS-mystery
Two oncologists in the city of Bergen in Norway have recently discovered a possible treatment for Chronic Fatigue Syndrome. The drug that they administered improved the condition of two out of three of the patients treated. Several patients were healed.
-
Apologize from the Norwegian Directorate of Health for the ME patients
The Health Directorate now say they are sorry that the services has not been good enough. " I think it is right to say that we have not developed good enough health services for those, and that I apologize for, says Guldvog."
-
Norwegian research Rituximab in ME/Chronic Fatigue Syndrome, PloS ONE, Fluge and Mella
Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study.
News
- 15.06.2009 Think Tank mentioned on Sky News
- 08.06.2009 Conference on ME/CFS in Stavanger is open for patients and relatives
- 10.12.2012 ESME to close
- 27.01.2012 Persbericht: Petitie ME-patiënten: Erken ME als invaliderende biomedische ziekte
- 24.01.2012 Response to ‘A controversial consensus’; By the International Consensus Panel, Journal of Internal Medicine